Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2017

Filed with the SEC on May 9, 2017 and accepted by EDGAR at May 9, 2017, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-01-01 to 2017-03-31$1.5mus-gaap:Revenues
Research and development3 months2017-01-01 to 2017-03-31$25.8mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-01-01 to 2017-03-31−$35.1mus-gaap:OperatingIncomeLoss
Net income3 months2017-01-01 to 2017-03-31−$34.3mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2017-01-01 to 2017-03-31−$0.28us-gaap:EarningsPerShareBasicAndDiluted
Capital expenditure3 months2017-01-01 to 2017-03-31$374.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2017-03-31$42.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-03-31$173.5mus-gaap:AssetsCurrent
Total assetsAt period end2017-03-31$360.0mus-gaap:Assets
Current liabilitiesAt period end2017-03-31$27.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-03-31$112.2mus-gaap:Liabilities
Shareholders' equityAt period end2017-03-31$247.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-17-031139. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.